Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
924012-43-1
Molecular formula
C15H15N
Molecular weight
209.29 g/mol
Drug class
Norepinephrine–dopamine–serotonin reuptake inhibitor (NDSRI)central nervous system stimulant
Mechanism of action
Inhibits the norepinephrine, dopamine and serotonin reuptake transporters. The mechanism by which centanafadine produces clinical benefit in ADHD is not fully established, but its efficacy may be mediated by increased availability of these monoamine neurotransmitters.
Indications / reported uses
Treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and paediatric patients aged 6 years and older weighing at least 20 kg under the US FDA SIMTRIYO indication (approved 24 July 2026); not recommended in children under 6 years or weighing less than 20 kg
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Centanafadine Environmental Risk Assessment (ERA) (the Centanafadine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.